OTCMKTS:DSNKY Daiichi Sankyo (DSNKY) Stock Price, News & Analysis → Elon’s New A.I. Device is About to Shock the World (From InvestorPlace) (Ad) Free DSNKY Stock Alerts $32.70 +0.50 (+1.55%) (As of 04/29/2024 ET) Add Compare Share Share Today's Range$32.40▼$32.8250-Day Range$29.15▼$34.2252-Week Range$23.72▼$37.57Volume154,487 shsAverage Volume137,499 shsMarket CapitalizationN/AP/E Ratio0.29Dividend Yield68.71%Price TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get Daiichi Sankyo alerts: Email Address Daiichi Sankyo MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthyDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment-0.11Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.74 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Daiichi Sankyo. Previous Next 4.0 Short Interest Percentage of Shares ShortedShort Interest Ratio / Days to CoverDaiichi Sankyo has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Daiichi Sankyo has recently decreased by 32.45%, indicating that investor sentiment is improving significantly. Previous Next 1.7 Dividend Strength Dividend YieldDaiichi Sankyo pays a meaningful dividend of 3.12%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthDaiichi Sankyo does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Daiichi Sankyo is 19.59%. This payout ratio is at a healthy, sustainable level, below 75%. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DSNKY. Previous Next 1.1 News and Social Media Coverage News SentimentDaiichi Sankyo has a news sentiment score of -0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Daiichi Sankyo this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Daiichi Sankyo insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.05% of the stock of Daiichi Sankyo is held by institutions. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Daiichi Sankyo is 0.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.30.Price to Earnings Ratio vs. SectorThe P/E ratio of Daiichi Sankyo is 0.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 188.48. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceElon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About Daiichi Sankyo Stock (OTCMKTS:DSNKY)Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.Read More DSNKY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DSNKY Stock News HeadlinesApril 29, 2024 | finance.yahoo.comAstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival ImprovementMarch 13, 2024 | msn.comMHRA authorises Daiichi Sankyo quizartinib for AML for marketingApril 30, 2024 | InvestorPlace (Ad)Elon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” March 2, 2024 | msn.comPfizer, Gilead, Roche seen benefitting the most from antibody-drug conjugatesFebruary 25, 2024 | wsj.comDaiichi Sankyo Co. Ltd. ADRFebruary 19, 2024 | finance.yahoo.comDatopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung CancerFebruary 16, 2024 | morningstar.comDaiichi Sankyo Co Ltd 4568February 16, 2024 | news.yahoo.comDaiichi invests 1 billion eur near Munich to make precision cancer drugsApril 30, 2024 | InvestorPlace (Ad)Elon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” February 16, 2024 | finance.yahoo.comDaiichi invests 1 bln eur near Munich to make precision cancer drugsFebruary 2, 2024 | finance.yahoo.comQ4 2023 Merck & Co Inc Earnings CallJanuary 25, 2024 | msn.comWhat's Going On With Pfizer Stock Today?January 17, 2024 | markets.businessinsider.comUS Patent Office Invalidates Seagen Patent In Daiichi Sankyo Dispute - Quick FactsJanuary 17, 2024 | finance.yahoo.comU.S. Patent Office Invalidates Seagen Patent in Dispute between Daiichi Sankyo and SeagenJanuary 3, 2024 | marketwatch.comEsperion Therapeutics, Daiichi Sankyo Europe Reach $125M Payment Agreement Over Commercial LitigationJanuary 3, 2024 | msn.comWhy Pharmaceutical Company Esperion Therapeutics Shares Are Diving TodayDecember 22, 2023 | markets.businessinsider.comMerck, Daiichi Sankyo Say FDA Grants Priority Review In U.S. For Patritumab DeruxtecanDecember 22, 2023 | finance.yahoo.comPatritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung CancerDecember 17, 2023 | msn.comDaiichi Sankyo Co., - ADR (DSNKY) Price Target Increased by 8.80% to 38.57December 12, 2023 | businesswire.comDepixus Announces Strategic Collaboration With Daiichi Sankyo to Use MAGNA™ Technology to Accelerate RNA-targeted Drug DiscoveryDecember 1, 2023 | baystreet.ca300,000 New Cases: The Role of Biotech in Addressing Rising Breast Cancer RatesDecember 1, 2023 | businesswire.comDaiichi Sankyo Demonstrates Breadth and Depth of Oncology Portfolio Across Multiple Cancers with New Data at ESMO Asia, SABCS and ASHNovember 27, 2023 | finance.yahoo.comJapan panel recommends approval of updated Daiichi Sankyo COVID shot- KyodoOctober 31, 2023 | investing.comDaiichi Sankyo Co., Ltd. (4568)October 31, 2023 | finance.yahoo.comMerck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?October 26, 2023 | finance.yahoo.comMerck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts SalesOctober 26, 2023 | finance.yahoo.com‘Guided Missile Drugs’ Could Be Big Pharma’s Secret WeaponSee More Headlines Receive DSNKY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Daiichi Sankyo and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - General Sub-IndustryN/A Current SymbolOTCMKTS:DSNKY CUSIPN/A CIKN/A Webwww.daiichisankyo.com Phone(136) 225-1111FaxN/AEmployees17,435Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio0.29 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Sunao Manabe D.V.M. (Age 70)Ph.D., Group CEO & Executive Chairperson Comp: $1.82MMr. Hiroyuki Okuzawa (Age 62)President, COO & Representative Director Comp: $713.24kMr. Masahiko Ohtsuki (Age 65)Senior Managing Exec. Officer, Head of Global DX, Chief Digital Transformation Officer & Director Comp: $713.24kDr. Shoji Hirashima (Age 63)Senior Managing Executive Officer, Head of Japan Business Unit & Representative Director Comp: $771.6kMr. Koji OgawaManaging Executive Officer, Head of Global Corporate Planning & Management and CFOChiyuGeneral Manager of Finance & Accounting DepartmentHiroto KashiwaseManaging Executive Officer, Head of Technology Management HQ and Head of Supply Chain HQNaoto TsukaguchiGen. Counsel, Corp. Officer, Head of Global Leg., IP, Global Compl. and Risk & VP of Leg. Aff. Dept.Kentaro AsakuraVice President of Corporate Communications DepartmentMs. Marielle Cohard-Radice M.D.Global Head of DevelopmentMore ExecutivesKey CompetitorsAstraZenecaOTCMKTS:AZNCFCosmo PharmaceuticalsOTC:CMOPFCSPC Pharmaceutical GroupOTCMKTS:CSPCYDechra PharmaceuticalsOTCMKTS:DCHPFJCR PharmaceuticalsOTCMKTS:JCRRFView All Competitors DSNKY Stock Analysis - Frequently Asked Questions Should I buy or sell Daiichi Sankyo stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Daiichi Sankyo in the last year. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" DSNKY shares. View DSNKY analyst ratings or view top-rated stocks. How have DSNKY shares performed in 2024? Daiichi Sankyo's stock was trading at $27.35 at the start of the year. Since then, DSNKY stock has increased by 19.6% and is now trading at $32.70. View the best growth stocks for 2024 here. Are investors shorting Daiichi Sankyo? Daiichi Sankyo saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 25,600 shares, a decline of 32.5% from the March 31st total of 37,900 shares. Based on an average daily volume of 116,800 shares, the short-interest ratio is presently 0.2 days. View Daiichi Sankyo's Short Interest. Is Daiichi Sankyo a good dividend stock? Daiichi Sankyo (OTCMKTS:DSNKY) pays an annual dividend of $22.47 per share and currently has a dividend yield of 3.12%. The dividend payout ratio is 19.59%. This payout ratio is at a healthy, sustainable level, below 75%. How do I buy shares of Daiichi Sankyo? Shares of DSNKY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:DSNKY) was last updated on 4/30/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI finds its first serious applicationWall Street StarForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportCharles Payne’s Gift to Stock InvestorsUnstoppable ProsperityHe Is Giving Away BitcoinCrypto Swap ProfitsWhy Big Pharma is Investing Billions in This BiotechBehind the MarketsElon Musk Secret Crypto Plot ExposedCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daiichi Sankyo Company, Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
